Main Article Content


An observational and comparative study was conducted at a tertiary care teaching hospital, Telangana state, India. A total of 100 patients from the In-patient department of Pulmonology in Gleneagles Global Hospital, who were diagnosed with Asthma, Chronic obstructive pulmonary disease, bronchiectasis, and those who have fulfilled the exclusion and inclusion criteria were selected for the study. Data was collected from the patient case records and information gathered with the help of patients and their attenders during ward rounds with the support of a physician which were analysed by SPSS software. Moreover, daily follow-ups were conducted to assemble data on amendment in therapy, everyday prognosis information and approaches in treatment leading to betterment in case study. Out of 100 patients considered in the study, 61(61%)  were male and 39(39%) were female,  to the study, patients having age between 60-70 has shown the highest diseased state of obstructive lung disease, past medical history of Asthma leading to the main cause of developing obstructive lung diseases, highest symptom noticed was productive cough with sputum, nebulization therapy showing highest efficacy in treating patients with obstructive lung disease and the major diagnostic criteria used in diagnosing obstructive lung disease is chest X-ray and HRCT. Emphysema is more evident than chronic bronchitis in COPD, Airway hyperresponsiveness is more evident than bronchoconstriction in Asthma.


Chronic obstructive pulmonary disease, Asthma, bronchiectasis, Clinical parameters, symptoms.

Article Details

How to Cite
G. Shravya Madhuri, Kasamsetty Srujana, J. Kranthirmai, & Shiv Kumar shete. (2023). A Study on Functional Status and Well Being in Obstructive Lung Diseases with Regard to Clinical Parameters and Symptoms – A Descriptive and Comparative Study. International Journal of Research in Pharmacology & Pharmacotherapeutics, 12(1), 47-62.


  1. 1. Mac Aogáin M, Chotirmall SH. Bronchiectasis and cough: an old relationship in need of renewed attention. Pulm Pharmacol Ther. 2019 Aug;57:101812. doi: 10.1016/j.pupt.2019.101812. PMID 31176801, PMCID PMC7110869.
  2. 2. Chandrasekaran R, Mac Aogáin M, Chalmers JD, Elborn SJ, Chotirmall SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018 May 22;18(1):83. doi: 10.1186/s12890-018-0638-0, PMID 29788932, PMCID PMC5964678.
  3. 3. Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: A narrative review. Respirology. 2020 Feb;25(2):161-72. doi: 10.1111/resp.13730. PMID 31713955, PMCID PMC7027745.
  4. 4. Eggert LE, He Z, Collins W, Lee AS, Dhondalay G, Jiang SY et al. Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy. 2022 Jan;77(1):173-85. doi: 10.1111/all.14972. PMID 34080210, PMCID PMC8222896.
  5. 5. Casara A, Turato G, Marin-Oto M, Semenzato U, Biondini D, Tinè M et al. Chronic bronchitis affects outcomes in smokers without chronic obstructive pulmonary disease (COPD). J Clin Med. 2022 Aug 20;11(16):4886. doi: 10.3390/jcm11164886, PMID 36013126, PMCID PMC9410001.
  6. 6. Kim V, Zhao H, Boriek AM, Anzueto A, Soler X, Bhatt SP et al. Persistent and newly developed chronic bronchitis are associated with worse outcomes in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016 Jul;13(7):1016-25. doi: 10.1513/AnnalsATS.201512-800OC, PMID 27158740, PMCID PMC5015750.
  7. 7. Anzueto A, Miravitlles M. Chronic obstructive pulmonary disease exacerbations: A need for action. Am J Med. 2018 Sep;131(9S):15-22. doi: 10.1016/j.amjmed.2018.05.003. PMID 29777660.
  8. 8. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Müllerova H, Donaldson GC et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007 Mar;29(3):527-34. doi: 10.1183/09031936.00092506. PMID 17107990.
  9. 9. Steurer-Stey C, Dalla Lana K, Braun J, Ter Riet G, Puhan MA. Effects of the ’Living well with COPD’ intervention in primary care: a comparative study. Eur Respir J. 2018 Jan 4;51(1):1701375. doi: 10.1183/13993003.01375-2017, PMID 29301921.
  10. 10. Amati F, Simonetta E, Gramegna A, Tarsia P, Contarini M, Blasi F et al. The biology of pulmonary exacerbations in bronchiectasis. Eur Respir Rev. 2019 Nov 20;28(154):190055. doi: 10.1183/16000617.0055-2019, PMID 31748420, PMCID PMC9488527.
  11. 11. Chalmers JD, Sethi S. Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017;27(1):18. doi: 10.1038/s41533-017-0019-9, PMID 28270656.
  12. 12. Chalmers JD, Elborn JS. Reclaiming the name ’bronchiectasis’. Thorax. 2015. - PubMed;70(5):399-400. doi: 10.1136/thoraxjnl-2015-206956, PMID 25791834.
  13. 13. McDonnell MJ, Rutherford RM. Other predisposing factors for bronchiectasis. Bronchiectasis. 2017:129-45.
  14. 14. Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc. 2015;12(12):1764-70. doi: 10.1513/AnnalsATS.201507-472OC, PMID 26431397.